美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

Tvardi Therapeutics Inc

1.06

+0.03002.91%

盘后：1.080.0200+1.89%19:30 EDT

成交量：24.82万

成交额：25.52万

市值：1,413.92万

市盈率：-0.38

高：1.08

开：1.02

低：0.9700

收：1.03

52周最高：43.65

52周最低：0.9300

股本：1,333.89万

流通股本：567.13万

量比：1.71

换手率：4.38%

股息：- -

股息率：- -

每股收益(TTM):-2.7737

每股收益(LYR):-3.2600

净资产收益率：-126.19%

总资产收益率：-55.51%

市净率：1.69

市盈率(LYR):-0.33

数据加载中...

总览公司新闻资讯公告

Tvardi Therapeutics公布TTI-109一期研究结果：药代动力学可预测，胃肠道耐受性良好

美国研究综述-应用材料公司、CME集团、纳斯达克

美国研究综述-应用材料公司、CME集团、纳斯达克

Piper Sandler将Tvardi Therapeutics评级上调至“增持”，目标价大幅提升至13美元

Tvardi股价上涨，其口腔炎症药物在早期临床试验中展现出良好前景

Tvardi Therapeutics旗下Tti-109展现快速转化与高达60%的Stat3驱动免疫细胞减少

Tvardi Therapeutics Tti-109 I期研究证实前药设计、耐受性改善及Stat3靶点参与的药效学证据

Tvardi Therapeutics 计划推进Tti-109用于STAT3驱动皮肤病及胃肠道疾病——需额外资金支持

Tvardi Therapeutics Inc：Tti-101治疗肝细胞癌二期试验顶线数据预计2026年下半年公布

Tvardi Therapeutics Inc：现金储备预计足以支撑运营至临床数据公布期及2026年第四季度

Tvardi Therapeutics Inc将于2026年6月公布Tti-109关键数据及临床开发战略

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hans/stock/TVRD/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TVRD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TVRD\",,,,,undefined,":{"symbol":"TVRD","market":"US","secType":"STK","nameCN":"Tvardi Therapeutics Inc","latestPrice":1.06,"timestamp":1791835200000,"preClose":1.03,"halted":0,"volume":248218,"hourTrading":{"tag":"盘后","latestPrice":1.08,"preClose":1.06,"latestTime":"19:30 EDT","volume":1050,"amount":1115.0500200000001,"timestamp":1791847801640,"change":0.02,"changeRate":0.018868,"amplitude":0.028302},"delay":0,"changeRate":0.029126213592233035,"floatShares":5671300,"shares":13338900,"eps":-2.773725,"marketStatus":"盘后交易","change":0.03,"latestTime":"10-12 19:35:35 EDT","open":1.02,"high":1.08,"low":0.97,"amount":255226.58416079998,"amplitude":0.106796,"askPrice":1.1,"askSize":1,"bidPrice":0.95,"bidSize":10,"shortable":3,"etf":0,"ttmEps":-2.773725,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1791849600000},"marketStatusCode":4,"adr":0,"listingDate":1391144400000,"exchange":"NASDAQ","adjPreClose":1.03,"preHourTrading":{"tag":"盘前","latestPrice":1.03,"preClose":1.03,"latestTime":"09:28 EDT","volume":5611,"amount":5783.1101307,"timestamp":1791811685623,"change":0,"changeRate":0,"amplitude":0.058252},"postHourTrading":{"tag":"盘后","latestPrice":1.08,"preClose":1.06,"latestTime":"19:30 EDT","volume":1050,"amount":1115.0500200000001,"timestamp":1791847801640,"change":0.02,"changeRate":0.018868,"amplitude":0.028302},"volumeRatio":1.714196,"impliedVol":1.6459,"impliedVolPercentile":0.51},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TVRD\",,,,,undefined,":{"symbol":"TVRD","floatShares":5671300,"roa":"-55.51%","roe":"-126.19%","lyrEps":-3.259999,"volumeRatio":1.714196,"shares":13338900,"dividePrice":0,"high":1.08,"amplitude":0.106796,"preClose":1.03,"low":0.97,"week52Low":0.93,"pbRate":"1.69","week52High":43.65,"institutionHeld":0,"latestPrice":1.06,"committee":0.818182,"eps":-2.773725,"divideRate":0,"volume":248218,"delay":0,"ttmEps":-2.773725,"open":1.02,"prevYearClose":4.3,"prevWeekClose":1.03,"prevMonthClose":1.25,"prevQuarterClose":1.25,"fiveDayClose":1.14,"twentyDayClose":1.83,"sixtyDayClose":3.2},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TVRD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-14","symbol":"TVRD","fiscalQuarterEnding":"2026/06","expectedEps":-0.65,"name":null,"time":"盘前","type":"earning","dateTimestamp":1786680000000,"reportTimeType":"pre","actualEps":-0.69},{"market":"US","date":"2026-05-08","symbol":"TVRD","fiscalQuarterEnding":"2026/03","expectedEps":-0.65,"name":null,"time":"盘前","type":"earning","dateTimestamp":1778212800000,"reportTimeType":"pre","actualEps":-0.73},{"market":"US","date":"2026-03-31","symbol":"TVRD","fiscalQuarterEnding":"2025/12","expectedEps":-0.55,"name":null,"time":"盘后","type":"earning","dateTimestamp":1774929600000,"reportTimeType":"post","actualEps":-0.78},{"market":"US","date":"2025-11-13","symbol":"TVRD","fiscalQuarterEnding":"2025/09","expectedEps":-0.83,"name":null,"time":"盘后","type":"earning","dateTimestamp":1763010000000,"reportTimeType":"post","actualEps":-0.59},{"market":"US","date":"2025-08-14","symbol":"TVRD","fiscalQuarterEnding":"2025/06","expectedEps":-0.51,"name":null,"time":"盘后","type":"earning","dateTimestamp":1755144000000,"reportTimeType":"post","actualEps":1}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TVRD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TVRD\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2222,"buy":0.5556,"hold":0.1111,"sell":0.1111,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5556,"analysts":9,"updateTime":1789099200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/TVRD\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"TVRD","date":"2026-10-09","current":-0.382158,"percent":0.993377,"low":-17.054928,"twenty":-2.558773,"median":-1.634574,"eighty":-1.325909,"high":-0.542504,"avg":-3.367826,"sd":4.162429,"marketCap":14406058},"quantilePoints":[{"date":"2025-08-01","current":-6.984237,"twenty":-7.018674,"median":-6.984237,"eighty":-6.867475,"marketCap":242869870},{"date":"2025-08-08","current":-6.220168,"twenty":-7.05634,"median":-6.986928,"eighty":-6.651705,"marketCap":216300131},{"date":"2025-08-15","current":-6.400424,"twenty":-7.003609,"median":-6.690985,"eighty":-6.397734,"marketCap":222568344},{"date":"2025-08-22","current":-10.573024,"twenty":-9.576632,"median":-6.986928,"eighty":-6.42948,"marketCap":249861702},{"date":"2025-08-29","current":-12.013447,"twenty":-10.759129,"median":-7.048807,"eighty":-6.480866,"marketCap":283901784},{"date":"2025-09-05","current":-12.078921,"twenty":-11.588463,"median":-7.134899,"eighty":-6.493511,"marketCap":285449060},{"date":"2025-09-12","current":-14.047103,"twenty":-11.928926,"median":-9.803211,"eighty":-6.612426,"marketCap":331961128},{"date":"2025-09-19","current":-15.372451,"twenty":-12.457478,"median":-10.666275,"eighty":-6.823352,"marketCap":363281754},{"date":"2025-09-26","current":-14.606606,"twenty":-13.432046,"median":-11.499578,"eighty":-6.955181,"marketCap":345183308},{"date":"2025-10-03","current":-14.82882,"twenty":-14.620891,"median":-11.737664,"eighty":-6.987466,"marketCap":350434671},{"date":"2025-10-10","current":-17.054928,"twenty":-14.850248,"median":-11.943013,"eighty":-6.991233,"marketCap":403042070},{"date":"2025-10-17","current":-2.571334,"twenty":-14.850248,"median":-11.769409,"eighty":-6.823352,"marketCap":60765765},{"date":"2025-10-24","current":-2.047544,"twenty":-14.833582,"median":-11.58886,"eighty":-6.422216,"marketCap":48387554},{"date":"2025-10-31","current":-1.849138,"twenty":-14.74787,"median":-11.130543,"eighty":-4.843171,"marketCap":43698837},{"date":"2025-11-07","current":-1.563435,"twenty":-14.662953,"median":-10.195062,"eighty":-2.595143,"marketCap":36947086},{"date":"2025-11-14","current":-1.631573,"twenty":-14.620891,"median":-9.523459,"eighty":-2.06421,"marketCap":38557323},{"date":"2025-11-21","current":-1.515552,"twenty":-14.489944,"median":-7.06764,"eighty":-1.887232,"marketCap":35836734},{"date":"2025-11-28","current":-1.634574,"twenty":-14.266143,"median":-6.990963,"eighty":-1.811838,"marketCap":38651137},{"date":"2025-12-05","current":-1.658378,"twenty":-13.805842,"median":-6.911597,"eighty":-1.667399,"marketCap":39214017},{"date":"2025-12-12","current":-1.781368,"twenty":-13.436014,"median":-6.493242,"eighty":-1.662637,"marketCap":42122234},{"date":"2025-12-19","current":-1.543324,"twenty":-13.412999,"median":-6.400424,"eighty":-1.660082,"marketCap":36493428},{"date":"2025-12-26","current":-1.5949,"twenty":-13.32332,"median":-6.349307,"eighty":-1.639335,"marketCap":37713002},{"date":"2026-01-02","current":-1.705987,"twenty":-13.031267,"median":-2.777676,"eighty":-1.642509,"marketCap":40339779},{"date":"2026-01-09","current":-1.678216,"twenty":-12.62652,"median":-2.62292,"eighty":-1.634574,"marketCap":39683085},{"date":"2026-01-16","current":-1.789303,"twenty":-12.344784,"median":-2.448323,"eighty":-1.634574,"marketCap":42309861},{"date":"2026-01-23","current":-1.91626,"twenty":-12.181298,"median":-2.07532,"eighty":-1.634574,"marketCap":45311891},{"date":"2026-01-30","current":-1.547291,"twenty":-12.091222,"median":-1.95231,"eighty":-1.634574,"marketCap":36587241},{"date":"2026-02-06","current":-1.408431,"twenty":-12.026542,"median":-1.896756,"eighty":-1.617117,"marketCap":33303771},{"date":"2026-02-13","current":-1.475877,"twenty":-11.900753,"median":-1.8627,"eighty":-1.598129,"marketCap":34898599},{"date":"2026-02-20","current":-1.424301,"twenty":-11.810677,"median":-1.847154,"eighty":-1.590139,"marketCap":33679024},{"date":"2026-02-27","current":-1.606802,"twenty":-11.750362,"median":-1.836912,"eighty":-1.577443,"marketCap":37994443},{"date":"2026-03-06","current":-1.5949,"twenty":-11.649572,"median":-1.807157,"eighty":-1.573476,"marketCap":37713002},{"date":"2026-03-13","current":-1.458024,"twenty":-11.588463,"median":-1.789617,"eighty":-1.565651,"marketCap":34476439},{"date":"2026-03-20","current":-1.460008,"twenty":-11.482118,"median":-1.781368,"eighty":-1.559193,"marketCap":34523345},{"date":"2026-03-27","current":-1.321148,"twenty":-11.243237,"median":-1.741999,"eighty":-1.553639,"marketCap":31239875},{"date":"2026-04-02","current":-1.545187,"twenty":-10.944836,"median":-1.71789,"eighty":-1.546029,"marketCap":28144032},{"date":"2026-04-10","current":-1.524584,"twenty":-10.628975,"median":-1.704004,"eighty":-1.543324,"marketCap":27768778},{"date":"2026-04-17","current":-1.6585,"twenty":-10.270654,"median":-1.682478,"eighty":-1.543324,"marketCap":30207927},{"date":"2026-04-24","current":-1.550337,"twenty":-9.805989,"median":-1.678216,"eighty":-1.544069,"marketCap":28237845},{"date":"2026-05-01","current":-1.622446,"twenty":-9.682977,"median":-1.674248,"eighty":-1.546029,"marketCap":29551233},{"date":"2026-05-08","current":-2.168412,"twenty":-8.568035,"median":-1.676379,"eighty":-1.548509,"marketCap":39495458},{"date":"2026-05-15","current":-2.406252,"twenty":-7.115528,"median":-1.682478,"eighty":-1.550705,"marketCap":37150122},{"date":"2026-05-22","current":-2.181425,"twenty":-7.071406,"median":-1.707971,"eighty":-1.552845,"marketCap":33679024},{"date":"2026-05-29","current":-2.120661,"twenty":-7.037507,"median":-1.719873,"eighty":-1.555226,"marketCap":32740890},{"date":"2026-06-05","current":-1.871529,"twenty":-6.991771,"median":-1.746061,"eighty":-1.555226,"marketCap":28894539},{"date":"2026-06-12","current":-1.646703,"twenty":-6.988542,"median":-1.736886,"eighty":-1.555278,"marketCap":25423442},{"date":"2026-06-18","current":-1.56771,"twenty":-6.984237,"median":-1.719873,"eighty":-1.555488,"marketCap":24203867},{"date":"2026-06-26","current":-1.434029,"twenty":-6.911597,"median":-1.705987,"eighty":-1.555226,"marketCap":22139971},{"date":"2026-07-02","current":-1.184897,"twenty":-6.735107,"median":-1.689237,"eighty":-1.549728,"marketCap":18293620},{"date":"2026-07-10","current":-2.30903,"twenty":-6.533867,"median":-1.695629,"eighty":-1.54687,"marketCap":35649107},{"date":"2026-07-17","current":-1.871529,"twenty":-6.492435,"median":-1.709955,"eighty":-1.549728,"marketCap":28894539},{"date":"2026-07-24","current":-1.555557,"twenty":-6.447775,"median":-1.713922,"eighty":-1.551074,"marketCap":24016240},{"date":"2026-07-31","current":-1.276043,"twenty":-6.414952,"median":-1.704004,"eighty":-1.544474,"marketCap":19700822},{"date":"2026-08-07","current":-1.124133,"twenty":-6.392353,"median":-1.682478,"eighty":-1.541737,"marketCap":17355486},{"date":"2026-08-14","current":-1.075522,"twenty":-6.364373,"median":-1.67765,"eighty":-1.526306,"marketCap":16604978},{"date":"2026-08-21","current":-0.658706,"twenty":-6.271824,"median":-1.674248,"eighty":-1.509204,"marketCap":17167859},{"date":"2026-08-28","current":-0.921233,"twenty":-4.310985,"median":-1.663144,"eighty":-1.491321,"marketCap":24010097},{"date":"2026-09-04","current":-0.946823,"twenty":-2.881884,"median":-1.6585,"eighty":-1.478258,"marketCap":24677044},{"date":"2026-09-11","current":-0.939146,"twenty":-2.728471,"median":-1.658378,"eighty":-1.472643,"marketCap":24476960},{"date":"2026-09-18","current":-0.82911,"twenty":-2.646728,"median":-1.653288,"eighty":-1.452073,"marketCap":21609087},{"date":"2026-09-25","current":-0.542504,"twenty":-2.6253,"median":-1.642509,"eighty":-1.430573,"marketCap":14139279},{"date":"2026-10-02","current":-0.634627,"twenty":-2.595143,"median":-1.636236,"eighty":-1.414779,"marketCap":16540289},{"date":"2026-10-09","current":-0.55274,"twenty":-2.558773,"median":-1.634574,"eighty":-1.325909,"marketCap":14406058}],"updateTime":1791848133435},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TVRD\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1134091137","title":"Tvardi Therapeutics公布TTI-109一期研究结果：药代动力学可预测，胃肠道耐受性良好","url":"https://stock-news.laohu8.com/highlight/detail?id=1134091137","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134091137?lang=zh_cn&edition=fundamental","pubTime":"2026-09-24 20:01","pubTimestamp":1790251275,"startTime":"0","endTime":"0","summary":"Tvardi Therapeutics Inc. 公布的一项一期研究显示，在研药物TTI-109展现出可预测的药代动力学特征，且胃肠道耐受性表现良好。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVRD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650941048","title":"美国研究综述-应用材料公司、CME集团、纳斯达克","url":"https://stock-news.laohu8.com/highlight/detail?id=2650941048","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650941048?lang=zh_cn&edition=fundamental","pubTime":"2026-07-09 15:29","pubTimestamp":1783582192,"startTime":"0","endTime":"0","summary":"美国研究综述-应用材料公司、CME集团、纳斯达克路透7月9日-周四，华尔街证券分析师调整了多家在美国上市公司的评级和目标股价，其中包括应用材料公司、CME集团和纳斯达克。股票条目按字母顺序排列。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260709:nL4S43B0L6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AX","COIN","FHB","MGM","RWT","ICE","NTRA","TECH","MKTX","BANR","ABBV","CZR","CME","WYNN","EXLS","ICHR","HSY","LRCX","EPAM","AMAT","TBBK","CL","WAT","LVS","RRR","TINY","LW","FDIG","TVRD","BLLN","CART","TW","VIRT","PKG","CFFN","CPF","PENN","CECO","COST","PLNT","PRM","BOH","LSEG.UK","AVAV","AA","LEVI","MTZ","FCNCA","NDAQ","KLAC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650094101","title":"美国研究综述-应用材料公司、CME集团、纳斯达克","url":"https://stock-news.laohu8.com/highlight/detail?id=2650094101","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650094101?lang=zh_cn&edition=fundamental","pubTime":"2026-07-09 15:29","pubTimestamp":1783582192,"startTime":"0","endTime":"0","summary":"美国研究综述-应用材料公司、CME集团、纳斯达克路透7月9日-周四，华尔街证券分析师调整了多家在美国上市公司的评级和目标股价，其中包括应用材料公司、CME集团和纳斯达克。股票条目按字母顺序排列。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260709:nL4T43B0L6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTZ","WAT","TW","FCNCA","WYNN","CPF","EXLS","MGM","CECO","LSEG.UK","ICE","MKTX","NDAQ","LVS","CZR","HSY","COIN","PKG","KLAC","PLNT","CART","BANR","BLLN","AX","NTRA","AMAT","CFFN","TBBK","TECH","ABBV","FHLC","AVAV","RWT","PENN","LW","COST","LEVI","ICHR","CL","TVRD","FHB","PRM","LRCX","RRR","BOH","WUGI","CME","VIRT","AA","EPAM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182444367","title":"Piper Sandler将Tvardi Therapeutics评级上调至“增持”，目标价大幅提升至13美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1182444367","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182444367?lang=zh_cn&edition=fundamental","pubTime":"2026-07-09 12:01","pubTimestamp":1783569678,"startTime":"0","endTime":"0","summary":"Piper Sandler发布最新研究报告，将生物制药公司Tvardi Therapeutics Inc的股票评级从“中性”显著上调至“增持”。与此同时，该机构大幅提高了其目标价，从此前的3美元跃升至13美元，显示出对公司未来发展前景的强烈信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TVRD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649982699","title":"Tvardi股价上涨，其口腔炎症药物在早期临床试验中展现出良好前景","url":"https://stock-news.laohu8.com/highlight/detail?id=2649982699","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649982699?lang=zh_cn&edition=fundamental","pubTime":"2026-07-07 19:48","pubTimestamp":1783424932,"startTime":"0","endTime":"0","summary":"BUZZ-Tvardi股价上涨，其口腔炎症药物在早期临床试验中展现出良好前景7月7日-** 药物开发商Tvardi Therapeutics（TVRD.O）的股价在盘前交易中上涨2%，至2.03美元** 该公司表示，其口服实验性药物TTI-109在早期研究中展现出的效果，与此前针对STAT3的药物TTI-101相当** 称TTI-109正在开发中，用于治疗与STAT3蛋白相关的炎症及异常细胞增殖所","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nL4T4390ZO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TVRD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157277204","title":"Tvardi Therapeutics旗下Tti-109展现快速转化与高达60%的Stat3驱动免疫细胞减少","url":"https://stock-news.laohu8.com/highlight/detail?id=1157277204","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157277204?lang=zh_cn&edition=fundamental","pubTime":"2026-07-07 19:05","pubTimestamp":1783422349,"startTime":"0","endTime":"0","summary":"Tvardi Therapeutics公司宣布，其候选药物Tti-109在临床前研究中表现出快速转化能力，并能够将Stat3驱动的免疫细胞数量减少高达60%。这一数据凸显了该药物在调节关键免疫信号通路方面的潜在效力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVRD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121974132","title":"Tvardi Therapeutics Tti-109 I期研究证实前药设计、耐受性改善及Stat3靶点参与的药效学证据","url":"https://stock-news.laohu8.com/highlight/detail?id=1121974132","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121974132?lang=zh_cn&edition=fundamental","pubTime":"2026-07-07 19:05","pubTimestamp":1783422322,"startTime":"0","endTime":"0","summary":"Tvardi Therapeutics公司近日公布了其候选药物Tti-109的I期临床研究数据。该数据有力地证实了其前体药物设计的合理性，同时显示出良好的耐受性改善，并提供了Stat3靶点参与的药效学证据。此外，在患者样本中观察到的药效学变化，为Stat3这一关键信号通路被有效抑制提供了直接证据。Stat3蛋白在多种肿瘤的发生与发展中扮演着核心角色，是肿瘤治疗领域备受关注的热门靶点。此次I期研究的积极结果，为Tti-109后续的临床开发奠定了重要基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVRD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121049283","title":"Tvardi Therapeutics 计划推进Tti-109用于STAT3驱动皮肤病及胃肠道疾病——需额外资金支持","url":"https://stock-news.laohu8.com/highlight/detail?id=1121049283","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121049283?lang=zh_cn&edition=fundamental","pubTime":"2026-07-07 19:04","pubTimestamp":1783422284,"startTime":"0","endTime":"0","summary":"Tvardi Therapeutics Inc 宣布，计划将其候选药物Tti-109的开发重点，拓展至由STAT3信号通路驱动的皮肤病和胃肠道疾病领域。然而，这一战略推进的实施，将取决于公司能否成功获得必要的额外资金。Tti-109旨在靶向并抑制STAT3的活性，从而可能为这些难治性疾病提供新的治疗选择。公司表示，新的开发计划将基于Tti-109已有的临床前数据及其作用机制的科学依据。此举标志着Tvardi在探索其核心资产Tti-109治疗潜力方面，迈出了战略性的一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TVRD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113723798","title":"Tvardi Therapeutics Inc：Tti-101治疗肝细胞癌二期试验顶线数据预计2026年下半年公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1113723798","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113723798?lang=zh_cn&edition=fundamental","pubTime":"2026-05-08 19:10","pubTimestamp":1778238637,"startTime":"0","endTime":"0","summary":"Tvardi Therapeutics Inc宣布，其核心候选药物Tti-101在肝细胞癌（HCC）患者中进行的二期临床试验，目前进展顺利。公司确认，该项研究的关键顶线数据仍按计划将于2026年下半年揭晓。\n这一重要里程碑的推进，标志着Tvardi公司在开发针对STAT3信号通路的新型口服小分子抑制剂方面取得了持续进展。Tti-101作为一种潜在的突破性疗法，旨在直接靶向STAT3，该靶点在多种实体瘤的生长和存活中扮演着关键角色。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVRD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165971805","title":"Tvardi Therapeutics Inc：现金储备预计足以支撑运营至临床数据公布期及2026年第四季度","url":"https://stock-news.laohu8.com/highlight/detail?id=1165971805","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165971805?lang=zh_cn&edition=fundamental","pubTime":"2026-05-08 19:10","pubTimestamp":1778238631,"startTime":"0","endTime":"0","summary":"生物制药公司Tvardi Therapeutics Inc近日宣布，其现有资金储备预计可充分支持公司运营至关键临床试验数据公布阶段，并持续维持至2026年第四季度。这一财务规划为公司在肿瘤治疗领域核心药物的临床开发提供了稳定保障。随着临床研究进入关键阶段，投资者可重点关注该公司在实体瘤和血液恶性肿瘤治疗领域的数据更新。稳定的现金储备为Tvardi Therapeutics在竞争激烈的生物科技赛道中提供了独特的续航优势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVRD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178271385","title":"Tvardi Therapeutics Inc将于2026年6月公布Tti-109关键数据及临床开发战略","url":"https://stock-news.laohu8.com/highlight/detail?id=1178271385","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178271385?lang=zh_cn&edition=fundamental","pubTime":"2026-05-08 19:10","pubTimestamp":1778238625,"startTime":"0","endTime":"0","summary":"生物制药公司Tvardi Therapeutics Inc近日透露，其核心候选药物Tti-109的关键临床试验数据以及后续临床开发战略，预计将在2026年6月正式对外公布。\n此次即将披露的顶线数据备受业界关注，其结果将直接影响该药物未来的研发路径与商业化前景。公司计划基于这些数据制定明确的临床推进策略，为后续研究阶段提供清晰方向。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVRD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":11,"code":"91000000","status":"200"}]}}